Here is a summary of the payments:
$26.6 million in options
$1 million base salary
$2.3 million in cash bonus
$116 million in perqs: car allowance, club membership, tax and financial planning services, insurance premiums.
$24.4 million in options
~$2 million cash bonus
$57.3 million in 500,000-share retention bonus
Yancopoulos's retention bonus was provided as incentive to stay employed at Regeneron and recognition of his expected "critical role" in the future success of Regeneron by developing new indications for Eylea and Zaltrap (a colon cancer treatment, marketed in partnership with Sanofi) and getting new drugs to market.
Regeneron Execs Score $140M Payday as Eylea Mints Money